Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control

Trial Profile

Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2017

At a glance

  • Drugs Candesartan cilexetil/chlortalidone (Primary) ; Losartan/hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors EMS
  • Most Recent Events

    • 17 Jan 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 22 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Aug 2017.
    • 22 Jul 2016 Planned primary completion date changed from 1 Oct 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top